Isu Abxis Co Ltd - ESG Rating & Company Profile powered by AI
The page contains a free E,S&G assessment covering Isu Abxis Co Ltd. Scroll down to the end of the webpage for potential risks for Isu Abxis Co Ltd based on sector, geography and size. The dashboard contains a questions and answers section for Isu Abxis Co Ltd.
Isu Abxis Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1967 | Hospira Inc | 0.3 | Low |
| 1967 | PRA Health Sciences Inc | 0.3 | Low |
| 1970 | Isu Abxis Co Ltd | 0.0 | Low |
| 1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
| 1970 | CTC Bio Inc | 0.0 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Isu Abxis Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose current and historical energy intensity?
Sign up for free to unlockDoes Isu Abxis Co Ltd report the average age of the workforce?
Sign up for free to unlockDoes Isu Abxis Co Ltd reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose its ethnicity pay gap?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose cybersecurity risks?
Sign up for free to unlockDoes Isu Abxis Co Ltd offer flexible work?
Sign up for free to unlockDoes Isu Abxis Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Isu Abxis Co Ltd conduct supply chain audits?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Isu Abxis Co Ltd conduct 360 degree staff reviews?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose the individual responsible for D&I?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose water use targets?
Sign up for free to unlockDoes Isu Abxis Co Ltd have careers partnerships with academic institutions?
Sign up for free to unlockDid Isu Abxis Co Ltd have a product recall in the last two years?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose incidents of discrimination?
Sign up for free to unlockDoes Isu Abxis Co Ltd allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Isu Abxis Co Ltd issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose parental leave metrics?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose the pay ratio of women to men?
Sign up for free to unlockDoes Isu Abxis Co Ltd support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Isu Abxis Co Ltd reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Isu Abxis Co Ltd involved in embryonic stem cell research?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose its waste policy?
Sign up for free to unlockDoes Isu Abxis Co Ltd report according to TCFD requirements?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose energy use targets?
Sign up for free to unlockDoes Isu Abxis Co Ltd disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Isu Abxis Co Ltd have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Isu Abxis Co Ltd
These potential risks are based on the size, segment and geographies of the company.
ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; and Clotinab, an abciximab that is used as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications. It is also developing ISU104, a human antibody for the treatment of refractory cancer; ISU304, a modified recombinant factor IX protein for the treatment of Hemophilia B patients; and ISU305, an antibody biosimilar for paroxysmal nocturnal hemoglobinuria therapy. ISU Abxis Co., Ltd. is headquartered in Seongnam, South Korea.